arginase

(redirected from Arginase 1)
Also found in: Medical, Encyclopedia.

ar·gi·nase

 (är′jə-nās′, -nāz)
n.
An enzyme found primarily in the liver that catalyzes the hydrolysis of arginine to form urea and ornithine.

[From German Arginin, arginine; see arginine.]

arginase

(ˈɑːdʒɪˌneɪz)
n
an enzyme which hydrolyses arginine into ornithine and urea

ar•gi•nase

(ˈɑr dʒəˌneɪs, -ˌneɪz)

n.
a liver enzyme that converts arginine to urea.
[1900–05; < German; see arginine, -ase]
References in periodicals archive ?
Aeglea BioTherapeutics presented 20-dose data on 14 patients from the company's completed Phase 1/2 trial and ongoing Phase 2 open-label extension, or OLE, trial for pegzilarginase in patients with Arginase 1 Deficiency, or ARG1-D, at the Symposium of the Society for the Study of Inborn Errors of Metabolism, or SSIEM.
Aeglea Bio Therapeutics Inc (NASDAQ: AGLE): Phase 1/2, 20-week repeat dose data for pegzilarginase in arginase 1 deficiency (Sept.
ENPNewswire-August 30, 2019--Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium
Newer immunomarkers of hepatocellular Differentiation, such as arginase 1 and glypican 3, have been successfully used in hepatoid carcinoma of other organs (pancreas, adrenal, lung, and stomach).
Additionally, the expression of the following four macrophage polarization markers transglutaminase 2 (Tgm2), arginase 1 (Arg1), chemokine (C-X-C motif) ligand 9 (Cxcl9), and nitric oxide synthase 2 (Nos2) was also assessed (example gating schema in Supplementary Figure 8).
It also inhibits the expression of inducible nitric oxide synthase and stimulates the expression of arginase 1, thereby preventing reactive nitric oxide production [5].
Unlike iNOS-mediated catabolism of arginine to NO in M1-like activated macrophages, M2-like activated macrophages catalyze arginine to urea and ornithine by arginase 1 (ARG1); ARG1 is a representative marker for M2-like activation.
He first encountered a patient with arginase 1 deficiency in 1972 and decided to make it the focus of his professional career.
However, the mRNA levels of OTC were extremely low in the non-AD subjects, and the normal cytoplasmic urea cycle enzyme arginase 1 (ARG1) was extremely low in both populations.
Target gene Primer sequence TNF [alpha] F: 5'-TTCTGTCTACTGAACTTCGGGGTGATCGGTCC-3' R: 5'-GTATGAGATAGCAAATCGGCTGACGGTGTGGG-3' Fizz1 F: 5'-TGGAGAATAAGGTCAAGGAAC-3' R: 5'-GTCAACGAGTAAGCACAGG-3' YM1 F: 5'-CATTCAGTCAGTTAT CAGATTCC-3' R: 5'-AGTGAGTAGCAGCCTTGG-3' iNOS F: 5'-GGCAGCCTGTGAGACCTTTG-3' R: 5'-GCATTGGAAGTGAAGCGTTTC-3' Arginase 1 F: 5'-AGACAGCAGAGGAGGTGAAGAG-3' R: 5'-CGAAGCAAGCCAAGGTTAAAGC-3' MMR F: 5'-AGTGGCAGGTGGCTTATG-3' R: 5'-GGTTCAGGAGTTGTTGTG-3' GAPDH F: 5'-ACCCAGAAGACTGTGGATGG-3' R: 5'-CACATTGGGGGTAGGAACAC-3' F, forward; R, reverse.
MDSCs can adopt multiple mechanisms to induce immunosuppression, including production of arginase 1 and inducible nitric oxide synthase, leading to T-cell inhibition [19,20].
In contrast, M2 microglia have an antiinflammatory phenotype, and express different molecules such as IL-4, arginase 1, Ym1, CD163, CD206, and IL10.